<DOC>
	<DOCNO>NCT02030067</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose RX-3117 subject advance metastatic solid tumor ( Phase 1 ) . The purpose Phase 2 portion estimate anti-tumor activity subject advanced malignancy ( relapsed refractory pancreatic advanced bladder cancer ) .</brief_summary>
	<brief_title>Dose-Finding Safety Study Oral Single-Agent Treat Advanced Malignancies</brief_title>
	<detailed_description>This dose-finding , open-label , single agent study RX-3117 . Once maximum tolerate dose identify additional subject treat dose expansion follow 2-stage Phase 2 study . Subjects treat 8 cycle therapy . A cycle 4 week . RX-3117 dose 3 time week 3 week follow 1 week treatment . All subject follow least 30 day last dose RX-3117 .</detailed_description>
	<criteria>Males females 18 year older Able swallow capsule Histological cytological evidence confirm metastatic pancreatic advance bladder cancer Able discontinue anticancer therapies 2 week prior study start Measurable evaluable disease use Response Evaluation Criteria Solid Tumors Life expectancy least 3 month ECOG performance status 0 1 Provide write informed consent Primary brain tumor clinical evidence active brain metastasis Systemic corticosteroid use within 7 day plan start study therapy Active infection require parenteral oral antibiotic within 2 week plan start study therapy Uncontrolled diabetes assessed investigator Prior current history hepatitis B , hepatitis C human immunodeficiency virus History bone marrow solid organ transplantation History congestive heart failure , arrhythmia , acute coronary syndrome torsades de pointes Any medical , psychiatric , social condition , opinion investigator , would preclude participation study , pose undue medical hazard , interfere conduct study , interfere interpretation study result Known hypersensitivity gemcitabine , azacytidine cytosine arabinoside Pregnant , plan pregnancy breast feeding study Concurrent participation another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>oncology</keyword>
	<keyword>tumor</keyword>
	<keyword>metastatic</keyword>
</DOC>